UBS Group
INMB icon

UBS Group’s INmune Bio INMB Stock Holding History

UBS Group’s Portfolio INMB Stock Details INMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$286K Buy
253,340
+192,537
+317% +$274K ﹤0.01% 6428
2025
Q4 		$94.9K Sell
60,803
-94,719
-61% -$169K ﹤0.01% 6938
2025
Q3 		$322K Sell
155,522
-293,699
-65% -$672K ﹤0.01% 6387
2025
Q2 		$1.04M Buy
449,221
+311,906
+227% +$2.29M ﹤0.01% 5424
2025
Q1 		$1.07M Buy
137,315
+1,067
+0.8% +$8.47K ﹤0.01% 5236
2024
Q4 		$636K Buy
136,248
+93,092
+216% +$485K ﹤0.01% 5673
2024
Q3 		$233K Buy
43,156
+2,863
+7% +$20.4K ﹤0.01% 5757
2024
Q2 		$355K Buy
40,293
+1,993
+5% +$19.6K ﹤0.01% 5258
2024
Q1 		$450K Sell
38,300
-4,915
-11% -$59.4K ﹤0.01% 5280
2023
Q4 		$487K Buy
43,215
+1,365
+3% +$11.4K ﹤0.01% 5137
2023
Q3 		$283K Sell
41,850
-10,400
-20% -$86.3K ﹤0.01% 5104
2023
Q2 		$474K Sell
52,250
-1,394
-3% -$11.2K ﹤0.01% 4866
2023
Q1 		$347K Buy
53,644
+8,614
+19% +$69.4K ﹤0.01% 4972
2022
Q4 		$285K Buy
45,030
+5,080
+13% +$36.1K ﹤0.01% 5169
2022
Q3 		$248K Buy
39,950
+1,000
+3% +$8.78K ﹤0.01% 4904
2022
Q2 		$344K Buy
38,950
+3,000
+8% +$22.3K ﹤0.01% 4550
2022
Q1 		$303K Hold
35,950
– – ﹤0.01% 5056
2021
Q4 		$367K Buy
35,950
+5,824
+19% +$86.2K ﹤0.01% 5220
2021
Q3 		$585K Buy
30,126
+22,680
+305% +$438K ﹤0.01% 4622
2021
Q2 		$131K Buy
7,446
+4,137
+125% +$55.7K ﹤0.01% 5671
2021
Q1 		$39K Buy
3,309
+3,059
+1,224% +$55.1K ﹤0.01% 6784
2020
Q4 		$4K Buy
+250
New +$2.35K ﹤0.01% 7911
2020
Q3 		– Sell
-820
Closed -$4K – 8193
2020
Q2 		$4K Sell
820
-309
-27% -$1.56K ﹤0.01% 7456
2020
Q1 		$4K Buy
1,129
+1,079
+2,158% +$4.87K ﹤0.01% 7392
2019
Q4 		$0 Sell
50
-636
-93% -$3.07K ﹤0.01% 8258
2019
Q3 		$4K Buy
686
+399
+139% +$2.95K ﹤0.01% 7552
2019
Q2 		$2K Sell
287
-922
-76% -$9.33K ﹤0.01% 7618
2019
Q1 		$9K Buy
+1,209
New +$9.36K ﹤0.01% 6876

Other funds holding INMB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return

UBS Group's INMB Position: Q1 2026 in Review

UBS Group increased its INmune Bio (INMB) stake by 317% in Q1 2026, buying an estimated $274K and bringing the position to 253,340 shares worth $286K. The position accounts for ﹤0.01% of the portfolio, ranked #6428.

UBS Group first reported a position in INMB in Q1 2019 and has held it in 28 quarters since. The position peaked at $1.07M in Q1 2025. 82 funds tracked by Wall St. Rank hold INMB as of Q1 2026.

  • UBS Group held 253,340 shares of INmune Bio worth $286K as of Q1 2026.
  • UBS Group bought 192,537 INmune Bio shares in Q1 2026, an estimated $274K.
  • INmune Bio made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6428 holding.
  • UBS Group first reported a position in INmune Bio in Q1 2019 and has held it in 28 quarters since.
  • UBS Group's INmune Bio position peaked at $1.07M in Q1 2025.
  • 82 funds tracked by Wall St. Rank held INmune Bio as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.